New American Society of Hematology guidelines raise ferritin cutoffs to catch iron deficiency sooner, including pregnancy and inflammation, and add TSAT for clearer diagnosis.
News|Videos|May 20, 2024
ETHOS Post-Hoc Analysis: Dave Singh, MD, Highlights Breztri Reduction of Cardiopulmonary Risk in COPD
Author(s)Grace Halsey
The triple therapy cut risk of a first cardiopulmonary event by 20% vs dual therapy in addition to significantly reducing COPD exacerbations, PI Singh told Patient Care.
Advertisement
Triple inhaled therapy with budesonide/glycopyrrolate/formoterol fumarate was more effective than 2 dual therapy formulations for reduction of the risk of a first cardiopulmonary event in persons with moderate to very severe chronic obstructive pulmonary disease, according to findings of a pivotal post-hoc analysis of the ETHOS phase 3 clinical trial presented at the American Thoracic Society 2024 International Conference. Principal investigator Dave Singh, MD, professor of respiratory pharmacology at the University of Manchester in Manchester, England, highlights the original study, rationale for the post-hoc analysis, and the encouraging findings in an interview with Patient Care® in the short video above.
Singh presented findings on behalf of the COURSE study group from Effect of triple inhaled therapy with budesonide/glycopyrrolate/formoterol fumarate on cardiopulmonary events in chronic cardiopulmonary events in chronic obstructive pulmonary disease: a post-hoc analysis of ETHOS at the 2024 American Thoracic Society International Conference, May 17-22, 2024, in San Diego, CA.
Advertisement
Related to this article
The US FDA cleared a novel insulin patch pump that can be used for up to 3 days with an additional 12-hour grace period in persons with diabetes.
Takeda’s oral TYK2 inhibitor showed rapid skin clearance in phase 3 psoriasis trials as FDA fast-tracks review; decision expected early 2027.
The FDA accepted Organon’s MIUDELLA supplemental application, but the proposed change, supporting data, and review timeline remain undisclosed.
Axsome has launched the SUMMIT phase 3 clinical trial evaluating AXS-05 to help adults quit smoking, comparing it with bupropion and placebo over 12 weeks.
A new scientific statement calls for a shift in obesity management and treatment to focus on overall health improvements rather than just weight loss alone.
New research underscores the need for public health interventions to improve the microbial and fiber content of diets in the US.
FDA awarded DT120 Breakthrough Therapy designation for MDD based on phase 3 data showing rapid, sustained improvement after one 100 μg dose.
Advertisement
Advertisement
Trending on Patient Care Online
1
ASH Raises Ferritin Thresholds for Diagnosing Iron Deficiency
2
Elevated PSA in Primary Care: What to Consider Before Biopsy
3
Combating Prostate Cancer Misconceptions in Primary Care: An Expert Discussion
4
FDA Grants Priority Review to Zasocitinib for Plaque Psoriasis
5